Security key
61023L207
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 5,529,904
- Total 13F value
- $360,987,109
- Share change
- +1,189,049
- SEC-reported price per share
- $65.30
- Number of holders
- 74
- Value change
- +$75,159,494
- Number of buys
- 55
- Number of sells
- 14
- Shares outstanding
- 6,646,654
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
74
Top holders
10
MNPR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 61023L207
Recent filing periods:
Ownership snapshot
Top reported holders of MNPR - Monopar Therapeutics - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
JANUS HENDERSON GROUP PLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
3/4/5
Lead comparable stake: 20%
13D/G row: JANUS HENDERSON GROUP PLC
Showing 1-6 of 15 holder rows.
Quick read
JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership
Top 5
JANUS HENDERSON GROUP PLC
20%
RA CAPITAL MANAGEMENT, L.P.
9.9%
ASTRAZENECA PLC
7.8%
Hendricks Diane
8.5%
Tactic Pharma LLC
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
20%
from 13D/G
|
$105,313,139
1,287,368 shares
|
— | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
9.9%
|
$43,402,756
667,632 shares
|
-$4,890,637 | 31 Dec 2025 |
| ASTRAZENECA PLC |
13D/G
|
7.8%
|
$34,126,392
522,667 shares
|
$0 | 31 Dec 2025 |
| Hendricks Diane |
3/4/5
10%+ Owner
|
8.5%
|
$50,213,802
567,580 shares
|
— | 16 Dec 2025 |
| Tactic Pharma LLC |
3/4/5
10%+ Owner
|
4.1%
|
$17,303,519
272,026 shares
|
-$34,999,957 | 24 Sep 2025 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
9.9%
|
$53,836,456
659,195 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
74
Shares
5,529,904
Rows available
74
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
55
Q4 2025 holders
74
Holder diff
19
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend